Economic implications of nonadherence to highly active antiretroviral treatment in HIV patients

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 2, 2006, Pages 135-143

  Lamiraud, Karine ^a   Moatti, Jean Paul ^b,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSERM   (France)

Author keywords

Cost analysis; Drug valuation; Economic analysis; Highly active antiretroviral treatment; Microeconomics

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ATTITUDE TO ILLNESS; BEHAVIOR THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; HEALTH ECONOMICS; HEALTH SERVICES RESEARCH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PSYCHOSOCIAL REHABILITATION; QUALITY ADJUSTED LIFE YEAR; REVIEW; STATISTICAL ANALYSIS; WELLBEING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HIV-1; HUMANS; PATIENT COMPLIANCE; TREATMENT REFUSAL;

EID: 33144484700     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.2.135     Document Type: Review

References (75)

1. CHESNEY MA, MORIN M, SHERR L: Adherence to HIV combination therapy. Soc. Sci. Med. (2000) 50(11):1599-1605.
2. SHERR L: Adherence-sticking to the evidence. AIDS Care (2000) 12:373-375.
3. HAUBRICH RH, LITTLE SJ, CURRIER JS et al.: The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS (1999) 13:1099-1107.
4. BANGSBERG DR, HECHT FM, CHARLEBOIS ED et al.: Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 14:357-366.
5. PATERSON DL, SWINDELLS S et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. (2000) 133:21-30.
6. BANGSBERG DR, PERRY S, CHARLEBOIS ED et al.: Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (2001) 15:1181-1183.
7. GARCIA DE OLALLA P. KNOBEL H, CARMONA A, GUELAR A, LOPEZ-COLOMES JL, CAYLA JA: Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J. Acquir. Immune Defic. Syndr. (2002) 30:105-110.
8. CARRIERI MP, RAFFI F, LEWDEN C et al.: Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3 year follow-up study. Antivir. Ther. (2003) 8:37-46.
9. SMITH PF, DICENZO R, MORSE GD: Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. (2001) 40:893-905.
10. JOLY V, YENI P: Non-nucleosidc reverse transcriptase inhibitors. Ann. Med. Intern (2000) 15:260-267.
11. MANGUM EM, GRAHAM KK: Lopinavir-ritonavir: a new protease inhibitor. Pharmacotherpy (2001) 21:1352-1363.
12. KATZENSTEIN DA: Adherence as a particular issue with protease inhibitors. J. Assoc. Nurses AIDS Care (1997) 8:10-17.
13. BANGSBERG DR, CHARLEBOIS ED, GRANT RM et al.: High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (2003) 17:1925-1932.
14. WALSH JC, POZNIAK AL, NELSON MR, MANDALIA S, GAZZARD BG: Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J. Acquir. Immune Defic. Syndr. (2002) 30:278-287.
15. CINGOLANI A, ANTINORI A, RIZZO MG et al.: Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (2002) 16:369-379.
16. SETHI AK, CELENTANO DD, GANGE SJ, MOORE RD, GALLANT JE: Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin. Infect. Dis. (2003) 37:1112-1118.
17. CARRIERI P, CAILLETON V, LE MOING V et al.: The dynamic of adherence to highly active antiretroviral therapy: results from the french national APROCO cohort. J. Acquir. Immune Defic. Syndr. (2001) 28:232-239.
18. HOWARD AA, ARNSTEN JH, LO Y et al.: A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 16:2175-2182.
19. TESORIERO J, FRENCH T, WEISS L, WATERS M, FINKELSTEIN R, AGINS B: Stability of adherence to highly active antiretroviral therapy over time among clients enrolled in the treatment adherence demonstration project. J. Acquir. Immune Defic. Syndr. (2003) 33:484-493.
20. HERTOGS K, BLOOR S, KEMP SD et al.: Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS (2000) 14:1203-1210.
21. HAYNES R, MCKIBBON K, KANANI R: Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet (1996) 100:258-268.
22. LERNER B, GULICK R, DUBLER N: Rethinking non-adherence: historical perspectives on triple-drug therapy for HIV disease. Ann. Intern. Med. (1998) 129:573-578.
23. SPIRE B, DURAN S, SOUVILLE M, LEPORT C, RAFFI F, MOATTI JP: Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc. Sci. Med. (2002) 54:1481-1496.
24. DURAN S, SPIRE B, RAFFI F et al.: Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin. Trials (2001) 2:38-45.
25. AMMASSARI A, MURRI R, PEZZOTTI P et al.: Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J. Acquir. Immune Defic. Syndr. (2001) 28:445-449.
26. ICKOVICS JR, CAMERON A, ZACKIN R et al.: Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir. Ther. (2002) 7:185-193.
27. DURAN S, SAVES M, SPIRE B et al.: Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS (2001) 15:2441-2444.
28. CARRIERI P, SPIRE B, DURAN S et al.: Health-related quality of life after 1 year of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (2003) 32:38-47.
29. NIEUWKERK PT, GISOLF EH, COLEBUNDERS R, WU AW, DANNER SA, SPRANGERS MA: Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/ saquinavir therapy: the Prometheus Study Group. AIDS (2000) 14:181-187.
30. TULDRA A, FUMAZ CR, FERRER MJ et al.: Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J. Acquir, Immune Defic. Syndr. (2000) 25:221-228.
31. PRADIER C, BENTZ L, SPIRE B et al.: Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy. French Prospective Controlled Study. HIV Clin. Trials (2003) 4:121-131.
32. GOUJARD C, BERNARD N, SOHIER N et al.: Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J. Acquir. Immune Defic. Syndr. (2003) 34:191-194.
33. FREEDBERG KA, LOSINA E, WEINSTEIN MC et al.: The cost effectiveness of combination antiretroviral therapy for HIV infection. N. Engl. J. Med. (2001) 344:824-831.
34. VALENTI WM: HAART is cost-effective and improves outcomes. AIDS Readers (2001) 11:260-262.
35. BOZZETTE SA, JOYCE G, MCCAFFREY DF et al.: Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N. Engl. J. Med. (2001) 344:817-823.
36. CLEEMPUT I, KESTELOOT, DEGEEST S: A review of the literature on the economics of non compliance: room for methodological improvement. Health Policy (2002) 59:65-94.
37. HUGHES DA, BAGUST A, HAYCOX A, WALLEY T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ. (2001) 10:601-615.
38. ELLIOTT RA, BARBER N: Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann. Pharmacother. (2005) 39(3):508-515.
39. RIZZO JA, SIMONS WR: Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin. Ther. (1997) 19:1446-57
40. MCCOMBS JS, NICHOL MB, NEWMAN CM, SCLAR DA: The cost of interrupting antihypertensive drug therapy in a Medicaid population. Med. Care (1994) 32:214-226.
41. GOLAN L, BIRKMEYER JD, WELCH HG: The cost-effectiveness of treating all patients Type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann. Intern. Med. (1999) 131:707-708.
42. LAFATA JE, MARTIN SA, KAATZ S, WARD RE: The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J. Gen. Intern. Med. (2000) 15:31-37.
43. TAYLOR JL, ZAGARI M, MURPHY K, FRESTON JW: Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch. Intern. Med. (1997) 157:87-97.
44. BROWN RE, KENDALL MJ, HALPERN MT: Cost analysis of once-daily ISMN versus twice-daily ISMN or transdermal patch for nitrate prophylaxis. J. Clin. Pharm. Ther. (1997) 22:67-76.
45. GENC M, MARDH PA: Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis. Pharmacoeconomics (1997) 12:374-383.
46. LAPIERRE Y, BENTKOVER J, SCHAINBAUM S, MANNERS S: Direct cost of depression: analysis of treatment costs of paroxetine versus imipramine in Canada. Can. J. Psychiatry (1995) 40:370-377.
47. ROCCHI A, TINGEY D: Economic evaluation of dorzolamide versus pilocarpine for primary open-angle glaucoma. Can. J. Ophtalmol. (1997) 32:414-418.
48. GLAZER WM, ERESHEFSKY L: A pharmacoeconomic model of outpatient antipsychotic therapy in revolving door schizophrenic patients. J. Clin. Psychiatry (1996) 57:337-345.
49. BILLUPS SJ, MALONE DC, CARTER BL: The relationship between drug therapy non-compliance and patient characteristics, health-related quality of life and health care costs. Pharmacotherapy (2000) 20:941-949.
50. HADDIX AC, HILLIS SD, KASSLER WJ: The cost-effectiveness of azithromycin for chlamdia trachomatis infections in women. Sex. Trans. Dis. (1995) 22:274-280.
51. SCOTT LL, ALEXANDER J: Cost-effectiveness of acyclovir suppression to prevent prevent recurrent genital herpes in term pregnancy. Am. J. Perinatol. (1998) 15:57-62.
52. BROWN MCJ, NIMMERRICHTER AA, GUEST JF: Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria. Eur. Psychiatry (1999) 14:230-244.
53. GARTON MJ, COOPER C, REID D: Perimenopausal bone density screening -- will it help prevent osteoporosis? Maturitas (1997) 26:35-43.
54. KOBELT G, JONSSON L, MATTIASSON A: Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol. Urodyn. (1998) 17:599-611.
55. REVICKI DA, BROWN RE, KELLER MB, GONZALES J, CULPEPPER L, HALES RE: Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J. Clin. Psychiatry (1997) 58:47-58.
56. CLARK WF, CHURCHILL DN, FORWELL L, MACDONALD G, FOSTER S: To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor for diabetic nephropathy. Can. Med. Ass. (2000) 162:195-198.
57. DRUMMOND MF, O'BRIEN B, STODDARD GL, TORRANCE GW: Methods for the Economics Evaluation of Health Care Programmes. Oxford University Press, Oxford (1997).
58. KAUF TL, JORDAN J: The cost-effectiveness of adherence. AIDS (2000) 14:S102-S102.
59. STRINGER JSA, DWIGHT JR, VERMUND SH, GOLDENBERG RL, SINKALA M, STINNETT AA: Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa. J. Acquired Immune Def. Syn. (2000) 24:369-377.
60. SCALERA A, BAYOUMI AM, OH PI, RISEBROUGH N, SHEAR NH, TSENG A: Clinical and economic implications of non-adherence to HAART in HIV infection. Disease Management and Health Outcomes (2002) 10(2):85-89.
61. STANSELL J, BARRETT J, DEGUZMAN C et al.: Incremental costs of HIV suppression in HIV therapeutic failure. Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2000) Abstr. 761.
62. GOLDIE SJ, PALTIEL AD, WEINSTEIN MC et al.: Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am. J. Med. (2003) 115(8):632-641.
63. ZARIC GS, BAYOUMI A, BRANDEAU ML, OWENS DK: Cost-Effectiveness of improved adherence to antiretroviral therapy. Value in Health (2003) 6(3):266.
64. LAMIRAUD K, GEOFFARD, PY: Therapeutic non adherence: a rational behaviour revealing patient preferences? Working paper Institute of Health Economics and Management (IEMS), Lausanne (2004).
65. JOHNSTON-ROBERTS, MANN T: Adherence to antiretroviral medications in HIV/AIDS care: a narrative exploration of one woman's foray into intentional non adherence. Health Care for Women International (2003) 24:552-564.
66. BECKER MH, MAIMAN LA: Sociobehavioural determinants of compliance with health care and medical care recommendation. Med. Care (1975) 13:10-24.
67. FISHBEIN M, AJZEN: Belief, attitude, intention and behaviour: an introduction to theory and research. Addison-Wesley, Don Mills, NY (1975).
68. CORONARY DRUG PROJECT: Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N. Engl. J. Med. (1980) 303:1038-1041.
69. IRVINE J, BAKER B, SMITH J et al.: Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhytmia Trial. Psychosom. Med. (1999) 61:566-575.
70. HORWITZ RI, VISCOLI CM, BERKMAN L et al.: Treatment adherence and risk of death after a myocardial infarction. Lancet (1990) 336:542-545.
71. GALLAGHER EJ, VISCOLI CM, HORWITZ RI: The relationship of treatment adherence to the risk of dealth after myocardial infarction in women. JAMA (1993) 270:742-744.
72. BOZZETTE SA, GIFFORD AL: The economic viability of antiretroviral adherence interventions. Am. J. Med. (2003) 115(8):672-673.
73. LUCE BR, ELIXHAUSER A: Estimating costs in economic evaluation of medical technologies. Int. J. Technol. Assess. Health Care (1990) 6:57-75.
74. PROTIÈRE C, DONALDSON C, LUCHINI S, MOATTI JP, SHACKLEY P: The impact of information on non-health attributes on willingness to pay for multiple health care programmes. Soc. Sci. Med. (2004) 58:1257-1269.
75. CLARKE PM: Cost-benefit analysis and mammographic screening: a travel cost approach. J. Health Econ. (1996) 17:767-787.